<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527966</url>
  </required_header>
  <id_info>
    <org_study_id>IRB G17008</org_study_id>
    <nct_id>NCT03527966</nct_id>
  </id_info>
  <brief_title>rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures</brief_title>
  <official_title>rhBMP-2 Versus Vivigen, a Novel Cellular Allograft, in Lumbar Fusion Procedures: a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virtua Health, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virtua Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed at comparing the overall efficacy (clinical and radiographic) of Vivigen,
      a novel cellular allograft product, and rhBMP-2 when utilized in lumbar fusion procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the overall efficacy (clinical outcome and
      radiographic fusion) of Vivigen (cellular allograft product) and rhBMP-2 in patients who
      undergo a single level lumbar instrumented fusion. Specifically, when compared to their
      control group counterparts treated to rhBMP-2, we hypothesize that the intervention group
      administered Vivigen would, following surgery, experience:

        1. Comparable mean postoperative leg/back pain score, where the pain scores are obtained
           using the numeric rating scale of 0-no pain, to 10-worst pain possible

        2. Comparable inpatient length of stay (LOS)

        3. Comparable postoperative Oswestry Disability Index (ODI) score (0-no disability, to
           100-maximum disability possible), two weeks, 6 weeks, 3 months, 6 months, and 1 year
           postoperatively

        4. Comparable fusion rates, evaluated via CT scan I year postoperatively
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left the institution
  </why_stopped>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 27, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The surgical team, including the surgeons, will be blinded to the treatment options until decompression/instrumentation have been completed. The patients and all staff, including hospital nursing staff, case management, and physical therapists, will be blinded as to which bone graft treatment the patient received.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Oswestry Disability Index (ODI) Score</measure>
    <time_frame>Up to 1 year post surgery</time_frame>
    <description>The ODI is one of the most commonly utilized condition-specific measures of disability used in the management of spinal disorders (0-no disability, to 100-maximum disability possible)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Postoperative Leg/Back Pain Score</measure>
    <time_frame>Average of 3 days in hospital</time_frame>
    <description>Pain scores are obtained using the numeric rating scale of 0-no pain, to 10-worst pain possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Inpatient Length of Stay</measure>
    <time_frame>Average of 3 days in hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fusion Rates, Evaluated Via CT Scan I Year Postoperatively</measure>
    <time_frame>1 year post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Lumbar Spine Degeneration</condition>
  <arm_group>
    <arm_group_label>Intervention group - 5cc Vivigen and local autograft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group - small kit rhBMP-2 with local autograft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>5cc Vivigen and local autograft</intervention_name>
    <description>The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft</description>
    <arm_group_label>Intervention group - 5cc Vivigen and local autograft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Small kit rhBMP-2 with local autograft</intervention_name>
    <description>The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft</description>
    <arm_group_label>Control group - small kit rhBMP-2 with local autograft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older;

          2. Diagnosed with lumbar degenerative/isthmic spondylolisthesis, degenerative disc
             disease with axial low back pain and neurologic symptoms, failed conservative
             treatment and eligible for a single level lumbar instrumented fusion;

          3. Willing to provide informed consent, participate in study, and comply with study
             protocol.

        Exclusion Criteria:

          1. Pregnant or contemplating pregnancy prior to surgery;

          2. Serious spinal conditions (e.g. spinal cord compression, cauda equina syndrome, spinal
             infection, spinal tumor, spinal fracture, inflammatory or systemic spinal arthritis);

          3. Surgery involving more than 2 vertebral levels;

          4. Worker's compensation or personal injury related to lumbar spine (treatment outcomes
             may be affected by patient's personal interests; could also run into potential issues
             with reimbursement).

          5. Lactating women

          6. Patients who have a known or suspected allergy to Gentamicin Sulfate, Meropenem,
             Vancomycin, Dimethyl Sulfoxide (DMSO), and Human Serum Albumin

          7. Immune compromised patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Virtua Memorial Hospital</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <results_first_submitted>July 12, 2019</results_first_submitted>
  <results_first_submitted_qc>July 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2019</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Plan to disseminate study findings via conference representation and journal publication using de-identified analyzed data</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03527966/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group - 5cc Vivigen and Local Autograft</title>
          <description>5cc Vivigen and local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft</description>
        </group>
        <group group_id="P2">
          <title>Control Group - Small Kit rhBMP-2 With Local Autograft</title>
          <description>Small kit rhBMP-2 with local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study was terminated early when PI left the practice. Three patients were randomized to the intervention group. Zero were randomized to the control group.</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group - 5cc Vivigen and Local Autograft</title>
          <description>5cc Vivigen and local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft</description>
        </group>
        <group group_id="B2">
          <title>Control Group - Small Kit rhBMP-2 With Local Autograft</title>
          <description>Small kit rhBMP-2 with local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="46" upper_limit="65"/>
                    <measurement group_id="B3" value="52.6" lower_limit="46" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Oswestry Disability Index (ODI) Score</title>
        <description>The ODI is one of the most commonly utilized condition-specific measures of disability used in the management of spinal disorders (0-no disability, to 100-maximum disability possible)</description>
        <time_frame>Up to 1 year post surgery</time_frame>
        <population>Patients did not attend every follow up visit and then were ultimately lost to follow up. Study was also terminated early when the PI left his practice so on patients were never randomized in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group - 5cc Vivigen and Local Autograft</title>
            <description>5cc Vivigen and local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Small Kit rhBMP-2 With Local Autograft</title>
            <description>Small kit rhBMP-2 with local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Oswestry Disability Index (ODI) Score</title>
          <description>The ODI is one of the most commonly utilized condition-specific measures of disability used in the management of spinal disorders (0-no disability, to 100-maximum disability possible)</description>
          <population>Patients did not attend every follow up visit and then were ultimately lost to follow up. Study was also terminated early when the PI left his practice so on patients were never randomized in the control group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ODI at Two weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="70" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODI at Six weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="26" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODI at Three months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" lower_limit="8" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODI at Six months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="36" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODI at 1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Postoperative Leg/Back Pain Score</title>
        <description>Pain scores are obtained using the numeric rating scale of 0-no pain, to 10-worst pain possible</description>
        <time_frame>Average of 3 days in hospital</time_frame>
        <population>Study was terminated early before any patients were randomized to the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group - 5cc Vivigen and Local Autograft</title>
            <description>5cc Vivigen and local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Small Kit rhBMP-2 With Local Autograft</title>
            <description>Small kit rhBMP-2 with local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Postoperative Leg/Back Pain Score</title>
          <description>Pain scores are obtained using the numeric rating scale of 0-no pain, to 10-worst pain possible</description>
          <population>Study was terminated early before any patients were randomized to the control group.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Inpatient Length of Stay</title>
        <time_frame>Average of 3 days in hospital</time_frame>
        <population>The study was terminated early before any patients were randomized to the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group - 5cc Vivigen and Local Autograft</title>
            <description>5cc Vivigen and local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Small Kit rhBMP-2 With Local Autograft</title>
            <description>Small kit rhBMP-2 with local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Inpatient Length of Stay</title>
          <population>The study was terminated early before any patients were randomized to the control group.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fusion Rates, Evaluated Via CT Scan I Year Postoperatively</title>
        <time_frame>1 year post surgery</time_frame>
        <population>No patient returned for their 1 year post op scan</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group - 5cc Vivigen and Local Autograft</title>
            <description>5cc Vivigen and local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Small Kit rhBMP-2 With Local Autograft</title>
            <description>Small kit rhBMP-2 with local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft</description>
          </group>
        </group_list>
        <measure>
          <title>Fusion Rates, Evaluated Via CT Scan I Year Postoperatively</title>
          <population>No patient returned for their 1 year post op scan</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Zero participants in the control group were at risk for all-cause mortality, serious adverse events, and other (not including serious) adverse events as the study was terminated early before any patients enrolled in that study arm. Adverse events collected per clinicaltrials.gov definitions. Protocol considered opioid related adverse events (ORAEs) an area of special interest but none were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group - 5cc Vivigen and Local Autograft</title>
          <description>5cc Vivigen and local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft</description>
        </group>
        <group group_id="E2">
          <title>Control Group - Small Kit rhBMP-2 With Local Autograft</title>
          <description>Small kit rhBMP-2 with local autograft: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jillian Hoopes</name_or_title>
      <organization>Virtua Health Inc.</organization>
      <phone>856-761-3904</phone>
      <email>jhoopes@virtua.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

